Abivax SA
ABVXHealthcare|Biotechnology|France
$139.90
-0.87 (-0.62%)
Tangible Book
$5.81
Earnings Power
$7.00
About
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Stock Price
+1585.5%(1Y)
Pipeline Summary
23 total trials7
Phase 1
15
Phase 2
6
Phase 3
0
Phase 4
Completed: 16Active: 2Recruiting: 3Terminated: 1Withdrawn: 1
Active Trials (5)
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
Phase 3Active
Enrollment: 1,116 participants
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
NCT03897543Carcinoma, Hepatocellular
Phase 1Phase 2Recruiting
Enrollment: 48 participants
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT05177835Ulcerative Colitis
Phase 2Active
Enrollment: 203 participants
Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation
NCT07453784Healthy
Phase 1Recruiting
Enrollment: 44 participants
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593Moderately to Severely Active Crohn Disease
Phase 2Recruiting
Enrollment: 212 participants
BioScore
4.9/10
Cautious
Ownership
Recent News
2026-07-10 13:51:38
2026-07-09 16:35:18
2026-07-03 16:50:44
2026-07-02 13:03:14
2026-07-01 14:30:34
Data last updated: Jul 13, 2026, 12:39 PM